Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PTGX
PTGX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PTGX News
Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates
5d ago
Barron's
Insider at Protagonist Therapeutics (PTGX.US) Plans to Sell $5.39 Million in Common Stock via Form 144
6d ago
moomoo
RTW Investments Takes New Stake in Apellis Pharmaceuticals
Mar 22 2026
Yahoo Finance
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
Mar 22 2026
Yahoo Finance
Icotyde Receives FDA Approval, Protagonist Hits Milestone
Mar 18 2026
stocktwits
Johnson & Johnson's Icotyde Receives FDA Approval
Mar 18 2026
CNBC
Johnson & Johnson's Icotyde Approved by FDA for Psoriasis
Mar 18 2026
Newsfilter
Johnson & Johnson's Icotyde Approved by FDA for Plaque Psoriasis
Mar 18 2026
seekingalpha
ICOTYDE Receives FDA Approval, Paving the Way for New Treatment Era
Mar 18 2026
Newsfilter
Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
Mar 02 2026
Newsfilter
Protagonist Therapeutics Reports Q4 Earnings Miss
Feb 25 2026
seekingalpha
BVF Fully Exits Protagonist Therapeutics with $170.12 Million Sale
Feb 25 2026
Fool
Protagonist Therapeutics Executive Executes Large Stock Sale
Feb 16 2026
Fool
Protagonist Therapeutics CMO Sells Shares in Major Transaction
Feb 01 2026
Fool
Protagonist Therapeutics Executive Sells Shares
Feb 01 2026
NASDAQ.COM
Protagonist CMO Sells 9,514 Shares for $784K to Cover Taxes
Feb 01 2026
Yahoo Finance
Show More News
